Advanced Solid Tumor Malignancies
Conditions
Keywords
Cancer, Advanced, Refractory
Brief summary
This study is for patients with advanced solid tumor malignancies (cancer that has spread to other parts of the body). The purpose of this study is to test the safety and effectiveness of a new combination of drugs, PD-0332991 and 5-Fluorouracil and Oxaliplatin for patients with advanced solid tumor malignancies . PD-0332991 stops cells from dividing by blocking an enzyme called cyclin-dependent kinase (CDK), which cancer cells need to grow and divide. By inhibiting this enzyme, PD-0332991 prevent cancer cells from growing and dividing, while the 5-Fluorouracil and Oxaliplatin damage the cells, hopefully increasing the killing of cancer cells, thus decreasing the tumors in the body. PD-0332991 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in colorectal cancer. It is given as a pill which is taken once a day for one week followed by one week off. 5-Fluorouracil and Oxaliplatin are administered as an infusion into a vein once every 2 weeks and are approved for and used as chemotherapy for several cancers.
Interventions
DRUGPD-0332991
Stage 1: PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10 Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules: Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3 In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
DRUG5-FU
Stage 1: PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10 Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules: Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3 In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
DRUGOxaliplatin
Stage 1: PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10 Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules: Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3 In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
Sponsors
Pfizer
Georgetown University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Retinoblastoma-positive, histologically proven advanced solid tumor malignancies for which no curative therapy exists * Biopsy accessible tumor deposits * Corrected QT interval less than 500 milliseconds by EKG * ECOG preformance status 0-2 * Subjects with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment. * Adequate hepatic, bone marrow, and renal function * Partial thromboplastin time must be \</= 1.5 x upper limit normal range and INR \< 1.5. Subjects on anticoagulant will be permitted to enroll as long as the INR is in acceptable therapeutic range. * Life expectancy \> 12 weeks * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months. * Subject is capable of understanding and complying with parameters of the protocol and able to sign and date the informed consent.
Exclusion criteria
* Intolerant of, or ineligible for 5-FU, oxaliplatin and/or the combination of both * CNS metastases that do not meet the criteria outlined in the inclusion criteria * Peripheral neuropathy \>/= Grade 2 at baseline or peripheral neuropathy \>/= Grade 1 with neuropathic pain * Active severe infection or known chronic infection with HIV or hepatitis B virus * Cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia or myocardial infarction, stroke, or congestive heart failure within the last 6 months. * Life-threatening visceral disease or other severe concurrent disease * Women who are pregnant or breastfeeding * Anticipated patient survival under 3 months * Concurrent use of known CYP 3A4 inhibiting or activating medications * Clinically significant and uncontrolled major medical condition(s)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 dose and schedule | 18 months | The dose and schedule of PD-0332991 to be used in combination with 5-FU |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trough level of PD-0332991 on Day 1 of Cycles 1-4 | 4 months | Determination of the effects of 5-FU on pharmacokinetics of PD-0332991 |
| Toxicity of the combination of PD-0332991, 5-FU, and oxaliplatin | 18 months | To quantify the adverse events |
| Pharmacodynamics | 18 months | evaluation of the effects of schedule of therapy on pharmacodynamic measures of PD-0332991 activity |
| Response rate | 18 months | Response rate as determined by RECIST 1.1 |
| Disease control rate | 4 months | Stable disease after four cycles + partial response + complete response |
Countries
United States
Outcome results
None listed